Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma-Reference-Cited by-同舟云学术

Prolonged SARS-CoV-2 Infection in Patients Receiving Anti-CD20 Monoclonal Antibodies: A Diagnostic Challenged by Negative Nasopharyngeal RT-PCR and Successful Treatment with COVID-19 High-Titer Convalescent Plasma

Published:2023-11-07 Issue:11 Volume:15 Page:2220
ISSN:1999-4915
Container-title:Viruses
language:en
Short-container-title:Viruses

Author:

Da Silva Léa¹,Klopfenstein Timothée¹^ORCID,Gendrin Vincent¹^ORCID,Clouet Julien¹,Toko Lynda¹,Richier Quentin²^ORCID,Leriche Thomas³,Nicolas Raoul⁴,Queijo Alexis¹,Sreiri Nour¹,Lacombe Karine²⁵,Zayet Souheil¹^ORCID

Affiliation:

1. Infectious Diseases Department, Nord Franche-Comté Hospital, 90400 Trevenans, France

2. Infectious Diseases Department, Assistance Publique Hopitaux de Paris, Saint-Antoine Hospital, 75012 Paris, France

3. Rheumatology Department, Nord Franche-Comte Hospital, 90400 Trevenans, France

4. Pneumologie Department, Nord Franche-Comte Hospital, 90400 Trevenans, France

5. INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP), Sorbonne University, 75646 Paris, France

Abstract

We highlighted in this current paper similar prolonged respiratory presentation with COVID-19 pneumonia in four severely immunocompromised patients currently being treated with anti-CD20 monoclonal antibodies (mAbs), such as ocrelizumab and rituximab, for multiple sclerosis or rheumatoid polyarthritis. Real-time reverse transcription-polymerase chain reaction on a nasopharyngeal swab specimen was negative in all patients. SARS-CoV-2 infection was confirmed from bronchoalveolar lavage fluid. A high titer of post-vaccine COVID-19 convalescent plasma was administered with complete recovery in all patients.

Publisher

MDPI AG

Subject

Virology,Infectious Diseases

Link

https://www.mdpi.com/1999-4915/15/11/2220/pdf

Reference21 articles.

1. Prolonged SARS-CoV-2 Illness in a Patient Receiving Ocrelizumab for Multiple Sclerosis;Gibson;Open Forum Infect. Dis.,2021

2. Negative Nasopharyngeal and Oropharyngeal Swabs Do Not Rule Out COVID-19;Winichakoon;J. Clin. Microbiol.,2020

3. Cognasse, F., Hamzeh-Cognasse, H., Rosa, M., Corseaux, D., Bonneaudeau, B., Pierre, C., Huet, J., Arthaud, C.A., Eyraud, M.A., and Prier, A. (2023). Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. EBioMedicine, 87.

4. Tomisti, L., Angelotti, F., Lenzi, M., Amadori, F., Sarteschi, G., Porcu, A., Capria, A.-L., Bertacca, G., Lombardi, S., and Bianchini, G. (2023). Efficacy of Convalescent Plasma to Treat Long-Standing COVID-19 in Patients with B-Cell Depletion. Life, 13.

5. Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach;Vita;Int. J. Infect. Dis.,2021